InsiderSignal.AI

InsiderSignal.ai

KYMR - Kymera Therapeutics, Inc.

Insider Sale by Mainolfi Nello (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Mainolfi Nello, serving as CEO at Kymera Therapeutics, Inc. (KYMR), sold 30,000 shares at $90.26 per share, for a total transaction value of $2,707,813.00. Following this transaction, Mainolfi Nello now holds 666,195 shares of KYMR.

This sale represents a 4.00% decrease in Mainolfi Nello's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, February 25, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, February 25, 2026, meaning the disclosure happened on the same day as the trade.

Kymera Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Mainolfi Nello

Mainolfi Nello

CEO

Nello Mainolfi, PhD is the Founder, President, and Chief Executive Officer of Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company pioneering targeted protein degradation therapies.[[1]](https://www.kymeratx.com/about-us/leadership/nello-mainolfi-phd/)[[2]](https://www.zoominfo.com/p/Nello-Mainolfi/11295847022) Under his leadership, Kymera has advanced a novel degrader platform, built a pipeline including clinical-stage programs like IRAK4, IRAKIMiD, and STAT3 for immune-inflammatory diseases and cancers, raised over $1 billion in capital, and formed partnerships with major biopharma firms.[[1]](https://www.kymeratx.com/about-us/leadership/nello-mainolfi-phd/)[[2]](https://www.zoominfo.com/p/Nello-Mainolfi/11295847022) Mainolfi began his career at Novartis Institutes for Biomedical Research, leading teams that identified investigational medicines including the FDA-approved factor B inhibitor iptacopan.[[1]](https://www.kymeratx.com/about-us/leadership/nello-mainolfi-phd/)[[3]](https://atlasventure.com/team/nello-mainolfi-phd/) Prior to founding Kymera in 2016, he served as Entrepreneur in Residence at Atlas Venture and Head of Drug Discovery at Raze Therapeutics.[[2]](https://www.zoominfo.com/p/Nello-Mainolfi/11295847022)[[3]](https://atlasventure.com/team/nello-mainolfi-phd/) He holds a PhD from The Scripps Research Institute and Imperial College London, with over 100 publications and patents.[[1]](https://www.kymeratx.com/about-us/leadership/nello-mainolfi-phd/) As a corporate insider, Mainolfi recently sold shares, including 100,000 on December 8, 2025, for $8.92 million, and 30,000 on December 31, 2025, under a Rule 10b5-1 plan.[[4]](https://www.investing.com/news/insider-trading-news/kymera-therapeutics-ceo-nello-mainolfi-sells-892-million-in-shares-93CH-4397383)[[6]](https://www.tradingview.com/news/tradingview:7b5521ff8aaca:0-kymera-therapeutics-ceo-sells-30-000-shares/)

View full insider profile →

Trade Price

$90.26

Quantity

30,000

Total Value

$2,707,813.00

Shares Owned

666,195

Trade Date

Wednesday, February 25, 2026

2 days ago

SEC Filing Date

Wednesday, February 25, 2026

HEALTHCAREBIOTECHNOLOGY

About Kymera Therapeutics, Inc.

Company Overview

No company information available
View news mentioning KYMR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4297153

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime